SGB-9768 not checked

Suzhou Sanegene Bio Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN, PNH - Paroxysmal Nocturnal Hemoglobinuria
Main trialPhase 2
“This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.”In the company’s words, NCT06786338 on ClinicalTrials.gov

Other drugs for IgA Nephropathy (IgAN)

All 39 drugs for IgA Nephropathy (IgAN)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 29 Dec 2026 A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
Phase 2Not yet recruiting 31 Aug 2027 Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 1Completed 7 May 2026 A Study of SGB-9768 in Adult Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SGB-9768

Following is part of Solo: you see every change to SGB-9768 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in